The discovery of additional mutations in LCH including A-RAF, N/KRAS, PIK3CA, and gene fusions involving B-RAF, ALK, and NTRK [28] enrich the variegate landscape of the histiocytosis and further complicate the therapeutic choice. The gene discussed is ALK; the disease is Histiocytosis.